Search clinical trials for: Oral Oxybutynin

Total 8287 results

Orient Pharma Co., Ltd.

Completed

A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease

Sialorrhoea

United States
Samantha Rodrigues Camargo Neves de Moura
Science Valley Research Institute

Recruiting

Topical Oxybutynin for Treatment of Hyperidrosis: Local or Systemic Effect? (TODAY)

Hyperhidrosis | Sweat Gland Diseases | Skin Diseases | Oxybutynin | Autonomic Agents | Cholinergic Antagonists | Parasympatholytics

Brazil
University of California, Davis

Recruiting

Oxybutynin for Post-surgical Bladder Pain and Urgency

Overactive Bladder Syndrome | Neuropathic Bladder

United States
Duramed Research

Completed

A Safety Extension Study of DR-OXY-301

Overactive Bladder

United States
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

The Effect of Extended-Release Oxybutynin Chloride on Vasomotor Symptoms in Healthy Post-Menopausal Women

Hot Flashes | Menopause
Watson Pharmaceuticals

Completed

Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers

Healthy Volunteers

United States
Universidad de Valparaiso
Uro Medical Corporation

Enrolling by invitation

Effectiveness of Oral Boldo in Women With Overactive Bladder

Urinary Bladder, Overactive

Chile
Watson Pharmaceuticals

Completed

A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition

Detrusor Hyperreflexia

United States
Bayer

Completed

Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.

Overactive Bladder

United States
Alza Corporation, DE, USA

Completed

Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder

Urinary Incontinence
Allergan

Completed

Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial

Overactive Bladder

United States
Janssen-Cilag Ltd.,Thailand

Terminated

Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity (RONDO)

Detrusor Function, Overactive

Thailand
Alza Corporation, DE, USA

Completed

A Study to Evaluate the Safety and Efficacy of OROS® Oxybutynin Chloride for the Treatment of Urge Urinary Incontinence

Urinary Incontinence
Janssen Korea, Ltd., Korea

Completed

An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants

Urinary Bladder, Overactive
Duramed Research

Completed

A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder

Overactive Bladder

United States, Canada
University of Colorado, Denver
Society for Pediatric Dermatology

Completed

A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults

Hyperhidrosis

United States
McNeil Consumer & Specialty Pharmaceuticals, a...

Completed

An Effectiveness and Safety Study Comparing Oxybutynin Chloride Plus FLOMAX (Tamsulosin HCl) and Placebo Plus FLOMAX (Tamsulosin HCl) for the Treatment of Lower Urinary Tract Symptoms.

Urination Disorders
US Department of Veterans Affairs

Completed

Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease

Overactive Bladder | Parkinson's Disease

United States
University Hospital, Bordeaux

Not yet recruiting

Early Oxybutinin Treatment for Boys With Posterior Urethral Valves (PRETIPUV)

Male Urogenital Diseases
Eastern Virginia Medical School
National Institutes of Health (NIH)

Completed

Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy

Diabetic; Neuropathic, Polyneuropathy (Manifestation)

United States
Watson Pharmaceuticals

Completed

Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder (MATRIX)

Quality of Life | Overactive Bladder | Urinary Incontinence

United States
Astellas Pharma Inc

Completed

Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis (SONIC)

Multiple Sclerosis | Spinal Cord Diseases | Neurogenic Bladder

Australia, France, Belgium, Germany, Netherlands, Italy, Spain, United Kingdom, Hungary, Czechia, Russian Federation
US Department of Veterans Affairs

Completed

Behavioral Treatment of Overactive Bladder in Men (MOTIVE)

Overactive Bladder

United States
Astellas Pharma Inc
Astellas Pharma Canada, Inc.

Completed

Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR) (VECTOR)

Overactive Bladder

Canada
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Effects Of Detrol LA On Memory And Cognition In Elderly Population

Cognition | Memory

United States
Stéphane Bolduc
Pfizer

Completed

Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children (FOXY)

Overactive Bladder
Watson Pharmaceuticals

Completed

Effects of Oxybutynin Topical Gel on Gastric Emptying

Healthy

United States
Federal University of São Paulo

Completed

A Study to Compare Oxybutynin to a Placebo in Women and the Effect on Plantar Hyperhidrosis

Hyperhidrosis
Astellas Pharma Inc

Terminated

Assessment and Tracking of Long-term Alefacept Safety (ATLAS)

Psoriasis

United States, Canada
University of Maryland, Baltimore
Food and Drug Administration (FDA)

Completed

Effect of Heat on Oxybutynin Release and Absorption From Oxybutynin Products

Heat Effect

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer

Prostate Carcinoma

United States
US Department of Veterans Affairs

Completed

Enhancing Conservative Treatment for Urge Incontinence (COMBO)

Urinary Incontinence

United States
Alza Corporation, DE, USA

Completed

A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence.

Urge Incontinence
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Oxybutynin Chloride in Managing Hot Flashes

Hot Flashes | Breast Carcinoma | Lobular Breast Carcinoma In Situ | Ductal Breast Carcinoma In Situ | No Evidence of Disease

United States
Buddhist Tzu Chi General Hospital

Completed

Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome

Overactive Bladder

Taiwan
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fed Study of Oxybutynin Chloride Extended-release Tablets 10 mg and Ditropan XL® Tablets 10 mg

Healthy

United States
FemmePharma Global Healthcare, Inc.

Completed

A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence (FP1097-002)

Urinary Incontinence, Urge

United States
Mylan Pharmaceuticals Inc

Completed

Food Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Food Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg

Healthy

United States
Duke University
Society of Urodynamics and Female Pelvic Medicine & Urogenital Reconstruction

Terminated

Comparison of Combination Therapy vs Single Agent Therapy for Treatment of Urge Incontinence. (APP)

Urinary Urge Incontinence

United States
Antares Pharma Inc.

Completed

Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence

Urinary Frequency | Urge Urinary Incontinence

United States
Toronto Rehabilitation Institute
Ontario Neurotrauma Foundation

Completed

Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity

Spinal Cord Injury | Neurogenic Detrusor Overactivity

Canada
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg

Healthy

United States
Watson Pharmaceuticals

Completed

Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition

Detrusor Hyperreflexia

United States
Eunice Kennedy Shriver National Institute of Child...

Terminated

Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones

Amenorrhea | Aplastic Anemia | Menorrhagia

United States
University of Arizona
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Recruiting

Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome (MOSAIC)

Obstructive Sleep Apnea | Down Syndrome

United States
University of Arizona
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Medications for Obstructive Sleep Apnea In Children With Down Syndrome (MOSAIC)

Obstructive Sleep Apnea | Down Syndrome

United States
Watson Pharmaceuticals

Completed

A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo

Overactive Bladder

United States

Search clinical trials for: Oral Oxybutynin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations